肺癌组织中端粒酶的表达及意义  

Expression and significance of telomerase in lung cancer

作　　者：李向阳[1] 阮淑芬[1] 

机构地区：[1]襄樊市中心医院,湖北襄樊441021

出　　处：《西部医学》2004年第4期299-303,共5页Medical Journal of West China

摘　　要：目的　探讨端粒酶活性在肺癌组织和肺良性疾病组织中的表达及端粒酶与肺癌组织学类型、淋巴结转移、肿瘤临床分期间的相关性。方法　采用 TRAP— PCR— EL ISA定量法及原位杂交定性方法 ,检测 4 4例手术切除标本端粒酶活性及 h TERT的表达 ,其中包括 30例肺癌组织和 14例良性病变及正常肺组织。结果　 1TRAP— PCR— EL ISA检测端粒酶活性肺癌组织明显高于肺良性病变和正常肺组织 (P<0 .0 1)。 2 30例肺癌组织中 h TERT阳性率与肺良性病变及正常组织中阳性率比较 ,两者差异具有显著性 (P<0 .0 5 ) ;32 2例肺癌伴有淋巴结转移者 ,端粒酶活性 ,h TERT阳性率均高于 8例肺癌不伴有淋巴结转移者 (P<0 .0 5 ) ;4端粒酶活性 ,h TERT阳性率在肺腺癌和肺鳞癌中差异无显著性 (P>0 .0 5 )。结论　 1端粒酶可能参与了肺癌的发生、发展 ;2端粒酶可作为病理学鉴别肺癌与良性病变的一个指标。Objective To study the activity of telomerase in lung cancer, lung benign lesion, and normal tissues, and to explore the correlation of telomerase with the histological classification, lymph node metastasis, and clinical stages of lung cancer. Methods The activity of telomerase was detected by TRAP-PCR-ELISA, and the expression of hTERT mRNA was examined using the in situ hybridization technique in samples resected surgically from 44 patients, including 30 lung cancer samples and 14 benign lesions or normal tissue samples. Results (1)The levels of telomerase activity in primary lung cancer tissues were significantly higher than those in benign lung lesion or normal tissues (P<0.01). (2)The positive rate in lung cancer tissue was 83.8%, and the positive rate of hTERT mRNA in benign lesion or normal tissue was 7.14%. There was a significant difference between them (P<0.05). (3)The level of telomerase and positive rate of hTERT mRNA in 22 lung cancer with lymph node metastasis were significantly higher than those without metastasis (P<0.05). (4) There was no significant difference in the level of telomerase and the expression of hTERT mRNA between squamous cell carcinoma and adenocarcinoma. (P>0.05). Conclusion Telomerase might contribute to the progression of lung cancer and could be used as a tumor marker in the diagnosis of lung cancer.

关 键 词：端粒酶 HTERT TRAP—PCR—ELISA 原位杂交 肺癌 

分 类 号：Q55[生物学—生物化学] R734.2[医药卫生—肿瘤]